MedTrace Logo

The Ischemia Modified Albumin In Diagnosing Ischemic New Events

NCT00355992 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 1250

Last updated 2009-05-12

No results posted yet for this study

Summary

The purpose of the study is to evaluate the utility of Ischemia Modified Albumin (IMA) for risk stratification in patients presenting with chest discomfort and possible ischemic heart disease, and to evaluate the diagnostic and prognostic implication for IMA for major adverse cardiac events.

Conditions

  • Heart Disease, Ischemic
  • Ischemia, Myocardial
  • Ischemic Heart Disease
  • Unstable Angina

Sponsors & Collaborators

  • Inverness Medical Innovations

    lead INDUSTRY

Principal Investigators

  • James L Januzzi, M.D. · Massachusetts General Hospital

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-09-30
Completion
2007-12-31

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00355992 on ClinicalTrials.gov